# Elizabeth A. Mittendorf

Source: https://onco.cc/people/elizabeth-mittendorf/  
OnCo record `elizabeth-mittendorf` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy.

## Summary

Elizabeth Mittendorf led IMpassion031, showing neoadjuvant atezolizumab plus chemotherapy raises pathological complete response in TNBC regardless of PD-L1 status, and ran the early HER2 peptide vaccine trials. As a breast surgeon she leads Alliance trials asking whether axillary surgery and radiotherapy can be omitted after excellent neoadjuvant response. She directs breast immuno-oncology at Dana-Farber.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: tnbc; surgery; immunotherapy
- Role: Director, Breast Immuno-Oncology Program, Dana-Farber Brigham Cancer Center
- Specialisms: Breast surgical oncology; Immunotherapy; Neoadjuvant trials; Tumour immunology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Mittendorf%20EA%5BAuthor%5D%20breast%20immunotherapy

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- journals: [Cancer Immunology Research](https://onco.cc/journals/cancer-immunology-research/)
- trials: [IMpassion031](https://onco.cc/trials/impassion031/)

---
JSON: https://onco.cc/api/v1/entities/elizabeth-mittendorf.json